Q1 2021 Zoetis Inc Earnings Call
[music].
Welcome to the first quarter 2021 financial results conference call and webcast for Us Airways.
Hosting the call today is Steve Frank Vice President of Investor Relations for us that with us.
Q good morning, everyone and welcome to the to let US first quarter of 2021 and earnings call and and joined today by Kristen Pack, our Chief Executive Officer, and Glenn David Our Chief Financial Officer for we begin it'll remind you. The slides presented on this call are available on the Investor Relations section of our website and on a remarks today will include forward look.
<unk> statements and that actual results could differ materially from those projections for.
For a lifted description of certain factors that could cause results to differ Ah refer you to the forward looking statement and today's press release on our SEC filings, including but not limited to our annual report on form 10-K, and a report on form 10-Q.
Ah remarks today and will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or us gap for reconciliation of these non-GAAP financial measures for the most directly comparable us GAAP measures is included in the financial tables that accompany our earnings press release and and the companies 8-K.
Filing David today, Thursday may 6th 2021.
We also played operational results, which exclude the impact on foreign exchange.
With that I will turn the call over to Crystal.
Thank you, Steve and good morning, everyone.
For you and your last line and tear off staying healthy and able to get back to me and for COVID-19, and if not already and Tim.
We've been very fortunate and the U S and vaccination rate, our app and infection rates are trending down on the rock, but that is not particularly should everywhere and many countries improving access to vaccine and controlling infection rates are critical hurdles for a more comprehensive global recovery, yeah with the extraordinary measures being taken back from any.
I remain optimistic about the steady progress, we're making to beat the pandemic.
And also very proud I've only been able to do it, though and and our own small way to support the global effort Steve.
We've been able to keep our colleagues safe encouraged and assistant with vaccinations, where possible and continue serving our customers and the care of their animals.
And we're off to a very strong start and 2021 executing on strategies for building on our innovative petcare portfolio, expanding and key market about five.
And accelerating our growth and diagnostics and the first quarter. We grew on top line revenue at 21% operationally, our best quarter ever with 25% operational growth internationally, and 19% growth and the us.
China, and Brazil letter International performance, with 75, and 48% operational growth, respectively, exhibiting their strength and both companion animal and livestock product sales.
And total are companion animal portfolio grew 34% operationally based on the strength of our parasiticide and dermatology products on our livestock portfolio grew 8% operationally with solid growth and cow swine and fish products.
And percent operationally and the first quarter, we've grown our point of care diagnostic sales made excellent progress on improving our connectivity solutions and veterinary practices and and seen are cloud beef benskin images platform, receiving very positive customer feedback with placements exceeding expectations and the early launch.
We're also making progress on a reference lagged integrations and look forward to future expansions and the face both in the us and internationally.
Our growth and my car was driven by the performance of catalyst line and fish and the first quarter channel product sales and the U S for strong as the foodservice sector is starting to recover and generic competition for Jackson with later than expected.
Meanwhile, swine and benefited from a continued recovery from African fly and fever and China.
Thanks for the unprecedented growth and revenue and our continued financial discipline and adaptability throughout COVID-19 are adjusted net income grew 34% operationally.
Looking ahead, we are raising guidance for operational growth and full year revenue to the range of 10, 5% to 12% and.
While we had unusually strong first quarter, we expect more normalised revenue growth and the second half of the year due to cover comparative quarters and increasing generic competition for Jackson.
Glenn will provide more dstl's detailed on other guidance update and his remarks.
Since the beginning of the year, the witness and continue to advance our key priority, including key milestones for new products and lifecycle innovations and geographic expansions for major brand.
Since our last earnings announcement, we received approval and the European Union for Collinsia. The first injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis and cats and Obi launching this year.
To us is vastly underdiagnosed and Undertreated today, too limited options for therapy, and difficulty recognizing pain and cats.
Meanwhile, Lirella are monoclonal antibody for the alleviation of OA opinion dogs has launched and Y-you and we're seeing a great customer response from back and dog owners, who referenced increased activity social ability and quality of life for their pets and.
The us we've continued discussions with the FDA regarding a regulatory commission and manufacturing inspection from a browser and Valencia, and we know anticipate approvals for both products and 2022 with low Bella likely later and the year.
By updates on us revenue expectations for these products and 2022 as we get further clarity on approval timing and rollout plan.
It is also worth noting that and China, which is our second largest market in terms of revenue. So it has recently received approvals for several meeting products for <unk> age and one chat vaccine for pigs, <unk> Z a key anti effective for cattle and swine and resolutions plus our latest parasiticide for cats we.
Continue to strengthen our portfolio and China, one of our key catalyst for growth.
And we're also maximizing our key brands with more geographic expansion and poultry we spend on our lineup recombinant vector vaccines with approval a pullback for certain HGTV, and Canada, Brazil, and several other smaller market and.
And and try and suicide receive additional approval for some Parker trio and Japan, Mexico and several other smaller market.
And turned sustainability, we published our long term goals and March with specific commitments to community animals and the planet.
We built for comprehensive and rigorous approach to are driven to care program and our goals include support for 10 of the 17, United Nations Sustainable development goal moving.
Be releasing more detail on these gold and our initial progress and our sustainability report this June.
In closing the fundamental growth drivers for our industry continue to show strong and sustainable momentum.
Pet adoption trends and higher spending per visit and the U S.
Low increased medical nation rates and market outside the us all continue to bode well for significant growth and are contained and animal and diagnostic portfolios globally. We.
We feel very confident about where our companion animals visit.
Come over the last few year lunch and innovative new products defining new standards of treatment and expanding our global reach.
And 2014 or companion animal business was 34% of our total revenue last year. It had grown to 55% based on the strength of on innovation and investment and growth and we see that continuing to expand.
And livestock the industry is and a more limited innovation cycle, and we spent and modest growth for the year like that growth is tied closely to the pandemic and how quickly the foodservice industry recovered.
For the way, we also anticipate increasing headwinds of generic competition to drag from but we expect our lifecycle innovation and competitive strategy to help us mitigate the impact.
Yeah.
Adjusted net income of $603 million.
It was an increase of 33% on a reported basis and 34% operationally.
Operational revenue grew 21%, resulting entirely from volume increases with price flat for the quarter.
Volume growth of 21% includes 13% from other in line products, 5% from new products and 3% from key dermatology products.
Companion animal products led the way in terms of species growth growing 34% operationally with livestock growing 8% operationally and the quarter.
Performance and companion animal was driven by our parasiticide portfolio, which include sales of <unk> and the us certain European markets, Canada, Australia and Mexico.
We also saw growth and our key dermatology products <unk> inside a point as well as and small animal vaccines and diagnostics.
Following blockbuster sales in year, one some parquetry will begin 2021 with strong first quarter performance posting revenue of $90 million growing sequentially each quarter since launch the.
And the underlying dynamics that drove first quarter sales are very favorable for significant future growth such as increasing clinic penetration and robust reordering rates within penetrated clinics.
And again like to mention how pleased we are with the performance of our broader parasiticide portfolio, which in addition to this and Paragon franchise had significant growth and the revolution stronghold and pro heart franchises as well.
U S market share within the fleet tick and Heartworm segment is now at an all time high of 31% representing an increase of more than 9% for the first quarter versus the same period and the prior year.
Global sales of our key dermatology portfolio were $245 million and the quarter growing 24% operation. We remain confident that key dermatology sales will exceed $1 billion. This year.
Our diagnostics portfolio grew 47% and Q1 led by increases of consumable and instrument revenue.
2020 presented challenging conditions for our diagnostics business as social distancing restrictions limited our ability to enter vet clinics and increase on market share. However.
However, our vast product portfolio commitment to innovation and ability to leverage the breadth of our medicines and vaccines portfolio has us well positioned to grow faster than the overall diagnostics market.
Livestock growth and the quarter was primarily driven by our cattle and swine businesses.
Improving market conditions from the COVID-19 recovery as well as successful promotional activities led to increased sales across the cattle portfolio.
In addition, later than expected timing of generic entrants led to strong first quarter sales for Jackson.
On slide portfolio grew 19% operationally as large producers continued rebuilding herds and as they recover from African swine fever, and created significant demand for our products.
Poultry sales declined and the first quarter as producers expanded their use of low cost alternatives to our premium products.
The decline and poultry, partially tempered the growth and cattle swine and fish.
Now, let's discuss the revenue growth by segment for the quarter.
U S revenue grew 19% with companion animal products growing 32% and livestock sales declining by 4%.
For companion animal pet ownership and pet spending trends remain promising.
And while severe weather caused a slight decline and vet clinic traffic for the quarter revenue per visit was up more than 10%.
In addition, pet ownership has increased and is trending towards a younger demographic and younger pet owners typically spend more on pet care.
This is a key driver for increased revenue per visit and creates a robust demand for our diverse portfolio.
Our small animal parasiticide portfolio was the largest contributor companion animal growth growing 74% and the quarter.
Diagnostics key dermatology products and small animal vaccines and also contributed to growth.
Some havoc for trio continues to perform well and the U S with sales of $83 million.
And <unk> franchise generated sales of $112 million and the quarter and is now the number two brand and the us flea tick and heartworm segment.
Companion animal diagnostic sales increased 62% and the quarter as the continued recovery at the vet clinic and a favorable prior year comparative period net.
The significant growth and point of care consumable revenue.
Key dermatology sales were $157 million for the quarter growing 16% with significant growth for optical and cytokine.
U S livestock declined 4% and the quarter driven primarily by poultry as producers switching to lower cost alternatives unfavorably impacted our business.
Swine also declined in the quarter, which is attributed almost entirely to a favorable nonrecurring government purchase which occurred in Q1 2020.
Cattle grew 6% and the quarter as promotional programs and the timing of generic entrance drove growth across the product portfolio.
Growth and Caddo, partially offset the declines and poultry and swine.
To summarize U S performance was once again strong and what remains a very favorable companion animal market environment in which we offer the broadest and most innovative product portfolio.
Although livestock declined in the quarter with expectations of further declines for the year. We are encouraged by a series of foodservice trends, such as increased dining out and school and business reopening.
Revenue and our international segment grew 25% operationally and the quarter with companion animal revenue growing 37% operationally and livestock revenue growing 17% operationally.
And the strength and companion animal was fueled by the continuing trends of pet adoptions, increasing standard of care by pet owners, and our investments and advertising all of which drove growth across our parasiticide and dermatology portfolios.
Companion animal diagnostics grew 18% and the quarter led by a 24% increase and point of care consumable revenue and a second consecutive quarter of double digit increase and instrument placement revenue.
We began early experience programs for La <unk> I'm on.
Monoclonal antibody for alleviation of OA pain in dogs.
The feedback from the programs has been extremely positive and further solidifies our view of the long term potential of the product with an EU launch currently underway.
Our feline monoclonal antibody <unk> will begin early experience programs and Q2.
With an EU launch to follow and the third quarter.
So when sales will provide cat owners and innovative therapy to address one of the largest unmet needs and animal health.
Our international livestock business, so double digit growth across all species with the exception of poultry, which grew low single digits and the quarter.
Swine revenue grew 29% operation led by growth in China of 128%, marking the third consecutive quarter with swine growth in excess of 100%.
While additional outbreaks and strains of African swine fever have occurred we believe it has continued to a specific region and a limited number of customers.
Cattle grew 11% operationally and the quarter as a result of marketing campaigns key account penetration and favorable export market conditions in Brazil, and several other emerging markets.
Our fish portfolio delivered another strong quarter growing 39% operationally driven by strong performance in Chile the <unk>.
<unk>, a seasonal vaccination protocols and the 2020 acquisition of Fischbeck group.
All major markets grew and the first quarter, many and double digits.
China total sales grew 75% operationally, which in addition to the significant growth and swine delivered 59% operational growth and companion animal.
Brazil grew 48% operationally and the quarter net sales of some Patrick the leading oral parasiticide and the Brazilian market drove a 73% operational increase and companion animal.
Overall, our international segment delivered strong results again, demonstrating the value of substantial geographic and species diversification.
Our companion animal business benefited from favorable trends, such as rising medicalization rates outside the us.
And while swine was the largest growth driver for our international livestock business. The contributions were broad based with growth across all species.
Now moving on to the rest of the P&L.
Adjusted gross margin of 71% increased 70 basis points on a reported basis compared to the prior year as a result of favorable product mix, partially offset by foreign exchange and other costs, including freight.
Adjusted operating expenses increased 8% operationally, resulting from increased compensation related costs and advertising and promotion expense for some power to trio.
This was partially offset by reductions to <unk> cost as a result of COVID-19.
The adjusted effective tax rate for the quarter was 19% and increase of 230 basis points.
Driven by a reduction and favorable discrete items compared to the prior year's comparable quarter, partially offset by the favorable impact of the jurisdictional mix of earnings.
Adjusted net income and adjusted diluted EPS grew 34% operationally for the quarter, primarily driven by revenue growth.
And we resumed our share repurchase program and the first quarter repurchasing approximately $180 million worth of shares.
Along with our dividend share repurchase is a critical component of our shareholder distribution strategy and.
We remain and a strong liquidity position and our highly cash generative and as a result, we expect to be able to execute on all investment priorities, including direct to consumer advertising internal R&D and external business development, while still returning excess cash to shareholders.
Now moving on to our updated guidance for 2021, which we are raising as a result of our first quarter performance.
Please note that our guidance reflects foreign exchange rates as of late April.
For revenue, we are raising and narrowing our guidance range with projected revenue NAV between seven five and $7 $6 5 billion.
And operational revenue growth between 10, 5% and 12% for the full year versus the 9% to 11% and our February guidance.
Adjusted net income is now expected to be and the range of $2, one two to $2 $1 $6 billion, representing operational growth of 12% to 14% compared to our prior guidance of 9% to 12%.
Adjusted diluted EPS is now expected to be and the range of $4 42 to $4 51.
And reported diluted EPS to be and the range of $4 eight to $4 and 19.
Our key assumptions for 2021 have not changed materially since the guidance, we provided on our Q4 2020 call.
However, our current view is that we will not face competition in the us for Sunpower for trio for our key dermatology products until the second half of 2022.
On our fourth quarter call I mentioned that we anticipated growth to be heavily weighted towards the first half for the year and I'd like to take this time to expand upon that further.
We are expecting first half 2021 growth to materially outpaced growth and the second half of the year, primarily resulting from some power for trio sales and the favorable Q2 2020 comparative period related to COVID-19.
Subsequently, we expect growth to moderate and the second half of the year as a result of increased generic competition for <unk> as well as challenging comparative periods, when pent up demand and the first half of 2020 worked its way through the system and the second half.
Now to summarize before we move to Q&A.
We have delivered strong operational top and bottom line growth and the first quarter with significant gains in both companion animal and livestock and across nearly every therapeutic area and geography.
In addition, we raised and narrowed our full year 2000, and 'twenty one guidance.
And while growth will moderate and the back half of the year for the reasons I outlined we again expect to grow faster than the market and feel very positive about our position for sustained growth beyond this year.
Now I'll hand things over to the operator to open the line for your questions operator.
And at this time, if you would like to ask a question. Please press star and one on your Touchtone phone.
We ask that you limit your questions to one and re queue with any follow ups volume will be muted after posing your question. Thank you.
We'll take our first question today from Erin Wright with Credit Suisse. Please go ahead.
Great. Thanks, so much cash.
And you speak a little bit more about the underlying changes being comfortable with lifestyle.
Paul will touch on quarter to date and it seems that blackman from Stifel, we'll pay down a little bit better and your ex.
And that team, but has anything changed in terms and how youre thinking about that headwind over the course of 2020 earnings.
And then my second question on cash that it does represent a larger portion of your portfolio and then Tony has historically I guess, how should we think about the seasonality of that day.
And your pattern for us across retailer and that clinic.
And did you see any sort of Paul forward outbreak blocking dynamic from the quarter that we should be aware of and what your guidance now calls for us.
And package for you.
Sure Thanks, Aaron and great to hear from you as you think about U S livestock as Glenn mentioned overall U S land pathways are down, 4%, but theres lots of different trends and their U S. Cattle was up 6% and the quarter and I think if you look at that that was driven by later than expected.
And trends and the generics and we were expecting more sooner.
And your point, we don't really think it's going to and find out any differently by the end and.
What do I mean by that if you look at that for you.
And hence will come we think once they do will likely end up and you look and generics is currently 20% to 40% penetration and what we said we think that might be what it's going to be electronics, and bolt and the U S and and the EU and it.
And really around the globe and.
As you think about guidance likely going to happen a little bit later and a year. So we can do better and the beginning of the year, but if you look at that and you compare us to how we did internationally on drafts and more specifically.
So, although you saw 6% growth and Jackson and the us internationally.
Overall, and grafts and internationally is actually down and because we did have multiple entrants sooner and that.
So I don't think lifestyle really is going to play out any differently.
As Glenn mentioned decline and poultry overall.
And there is some seasonality obviously, you think about cattle and swine was down and poultry, but overall I think we continue to remind US you look at life back overall for us.
About 8% and I think often people under appreciate it. Thanks.
Steve for kind of livestock us outside of the U S and us although we focus a lot on U S cattle the growth that you saw in China.
Across wine with 128% growth and in Brazil, still net livestock did quite well as.
And as you think about that parasiticide I'll, let Glenn and started to take some of that and get into some of the margin specific trends.
Yes. So thanks are and so from a parasiticide perspective, we've had a really strong quarter with us some power for franchise, 133% growth and the franchise great performance from some power to trio with $90 million and the quarter alone and some powered for also delivering $74 million with 38% growth in terms of seasonality that we typically do see.
Juan and particularly Q2 being the stronger quarters from our parasiticide portfolio perspective, particularly in the US. However, as we do see some power <unk> trio on a ramp up curve the impact of that seasonality may be a little different this year as we do expect to continue to increase our clinic penetration and adoption and market share within the clinics as well so.
It definitely has some seasonality within the parasiticide portfolio, but with the continued ramp up on the product and maybe not be as severe as you would typically see with an established product.
Thank you. Our next question is from Michael risk and with Bank of America. Please go ahead.
Thanks Christie Bryan Thanks, taking my question.
And I want to start on China, just really incredible growth. This year. This quarter, obviously, you highlighted some of the aspects there.
African swine fever, bounce back and then companions and doing well there for a while and Peter and that continues to grow and just wondering if you could opine on how sustainable that AIDS and may not.
And one 3 million number.
And you jumping off point that we should be thinking about in terms of run rate going forward and obviously growing from that or could there have been some some bulk orders for.
For example, and swine and some of these producers restart their operations and.
Indicative of what the guidance range would indicate for the year, but there'll be different dynamics throughout the quarters to that so for Q1 with the growth of 8%.
Really was driven by a lot of the incremental DPC that we had for us and parrack, a trio and the quarter and also we didn't have the savings from teeny and queue Juan.
We have the savings from Teeny and Q1, because and Q1 of 2020 that was free COVID-19, we still had our elevated <unk> spend as we move throughout the year, obviously, we're not going to have that benefit so the impact of the incremental DTC for some parakeets for you will be there, but we also increased our spending for DTC for some fabric and trio throughout the year last year. So.
Number of different factors, but the overall level of growth for the year perspective is pretty similar to what we saw for the quarter.
And our next questions John Block with Stifel. Please go ahead.
Great. Thanks, guys good morning.
First of all Glenn for you just simply overall topline steps on.
And do we attribute done solely to companion animal it seems like livestock just based on your comments links and there'll be an upload single digit range and maybe more specifically.
And the step up and companion just due to trio.
And have you annualize up and $90 million you get the 360 already and it seems like that was in and around the original guidance on and we think about the contribution to growth.
And then Christian maybe just to give us.
Can you give a little or color on what you are seeing and the poultry market for those lower and competitive dynamics specific specific to the U S and and.
Surface and international and maybe what's gonna be the wettest us response and coming quarters. Thanks, guys.
Sure. It's it's on on in terms of the overall topline step up and the guidance. There are a number of factors that drove that beyond just companion animals, obviously very pleased with the performance of some purgatorial and that is definitely one of the drivers for the guidance range, but is Kristen mentioned also very strong performance and China off to a very strong start to the year.
I think this is also driving important growth and our diagnostics business.
<unk> grew 47% on the quarter again can't tell you what's wrong with them. So I think thats were getting really increased focus on doing diagnostic tests and a lot of these wellness visits and as you.
About livestock I mean, there's two trends and look at one is just when will we produce more protein as people go out more really what youre going to need to see to see significant improvements here globally is an increase and travel and entertainment and.
I think we're now seeing people going back to school, maybe going back to work, maybe traveling for personal but getting that travel and entertainment industry backup will help drive the growth and livestock globally I think over some of these coming quarters, so slightly different trends, but we continue to remain bullish and on.
For the way, we see our growth is with an increasing pet care business, we see great growth and pet care from everything from our inline our Perez our derm our nomad.
Looking at increased growth in China, and Brazil, which again as we talked about we think is sustainable and.
And then lastly continued investment and growth and our diagnostics business, which we're quite excited about.
Thank you on the next question is from John Kreger with William Blair. Please go ahead.
Alright, Thanks, very much question about labella now that that product is launched and the E U.
Can you talk a little bit more about the clinical differentiation.
And we're seeing compared to some of the existing oral alternatives.
Sure, where and you probably know we.
Began the early experience and the.
And you and we'll be launching formally and Q2 for liver Ella.
Early experience information that we saw was really really positive on.
Both obviously, it's got a strong safety profile, but the efficacy it's working very quickly faster than I think some of our customers expected and are seeing significant improvements and the quality of life and and the pain of these dogs. So we remain very bullish that customers are looking for an alternative to the products on the market right now.
And we're seeing a really strong uptake and that this is still a significant market.
You look at sort of 90 million dogs in the EU today, 40% of those dogs have OA and currently only 28% of those are treated so the early experience day.
And to that we've seen to date and the early launch makes us very optimistic for the success of this product and as we mentioned before we expect this product and be a blockbuster.
And our next question is from David West of Bird with Guggenheim Securities. Please go ahead.
Hi, Congrats on a great quarter and thanks for taking the question. So can you remind us why there is such a species by species differences and the U S and international livestock market and given that protein and inherently global.
And then for my second question on the diagnostic portfolio I think confirmed 46% debt.
And the huge number so can you just talk about the components of growth and of that and if some of that are and then kind of the organic growth rate there on thank you.
Yes.
Okay I'll take the first question and then Glenn can take the second one.
Although protein and global the dynamics are very different and.
Each species and a few ways one obviously if you.
We look at consumption and people.
Moving to the Middle class they are generally starting with milk and eggs and poultry.
They move up to swine and beef. There's also differences geographically on what people consume obviously, China and the huge fly and market that's not true and the US are you see probably more poultry and beef. So there really are different consumption trends.
And as well the other real big differences and two producers and each market and three species, how much is exported and the.
<unk> is a significantly larger export market for poultry and swine and so they're very different dynamics.
For each of the different species as people trade up and trade down different protein sources. As you think about where people are sourcing those protein and towards the towards the export markets versus internal production, so and it does lead to very different dynamics. The other major dynamic and you should think about us that the ability for each.
<unk> to change their supply is actually quite different once you have and supply of cattle. They take many years to grow and you can't all of a sudden pare back and cattle and poultry producers can decide not to use a bunch of eggs and grow chicken, but you can only take a few months. So it is very different and their ability to react to the market.
And therefore, you do see different decisions being made and you probably saw on the papers today there is.
Huge demand for poultry right now and I think poultry producers are going to have to us or to start scaling up and they can do that quickly. They can make those decisions and expand their flock very quickly and it's a very difficult thing and it takes a lot of time for a swine or a cattle producers. So that's why you sometimes see some of these different dynamics across species and regarding diagnostics, a very strong quarter for.
Our diverse portfolio and grew 47% and the quarter overall and that growth was really balance and for many.
Many different areas. So we saw the us grew 59% and the quarter and diagnostics with strong growth and our consumables really pulling through the increased incremental placements instrument placements that we saw last year really drove increased consumables and the quarter also strong performance for our reference lab business and increased growth and our instrument revenue.
At 300 basis points.
Step up how much of that is just sort of increase in normalized baseline expenditure vs targeted investments spin and how should we be thinking about the progression of SG&A levels.
Over the balance of the year relative to some of the and.
Investment programs that you have a budget of thanks.
Sure and thanks, how are you and I think the first question yet Glenn.
Glenn mentioned and his opening remarks, we are not expecting a competition and the fourth and parakeet trio order for our Derek for kind of alcohol us beta point.
And told me the make the second half of 2022 at the earliest to be honest with you and this is this based on a competitive intelligence, which is as we said from the start is not perfect. There is not great information, but we definitely unexpected this year and based on what we've heard we don't think it's and the first half of next year at the earliest though.
And that we are always prepared for competition to come and.
Never exactly clear when it will be but I think our we're very optimistic that we've got at the very least this year and the first half of next year and will be aggressive and growing these products as as we've seen but I would remind you on.
If you look at it compared to trio, we've done incredibly relative Erica and it was the third for market and we continue to grow this franchise.
Already around the world.
It's imperative franchise seasonal even with other competitors on the market, so I'm going to us and you want to add their Glenn and are you guys on the second question.
To the to the second question in terms of the author extend and what we see so there are a number of different areas that are driving us incremental on this year part of it is a bit of a normalization from the COVID-19 impact and 2020, we would expect us to new expenditures would begin to increase particularly and the second half of the year, but also a compensation costs as we.
Of hiring some solutions that may have been on hold would be impacted COVID-19 or just more difficult to fill we are increasing our higher and really to support the strength of many of our key brands and to continue the growth there.
From a DTC spending perspective, we would expect more DTC spending this year dream about a couple of different factors and we have some power vitriol on the market for the full year. So we will support the with advertising expenditures for the for you as well and we also continue to see strong growth and many of our brands such as our dermatology portfolio and will continue to increase and support though.
Brands for direct to consumer advertising, not only and the us but outside of the us as well, where we are increasing our GTC spent behind many of our brands, including some pyric as well as our dermatology portfolio. So the number of areas on spend really to support the significant revenue growth opportunities that we see not only for this year, but for many years.
And.
Our next question is from the largely per smog with Barclays. Please go ahead.
Good morning, and thanks for the questions.
From Maine on following up on the broiler could you maybe give us some thoughts on the gross margin impact on be 40 to 60 pound for.
Nice points on them and to deal with that and what's your and expectations around us age of this product and Tony's knew them all laying on the recommendation is.
And once a month and junction so on two on and and the pasture wellbeing.
Quiet about anthrax vaccines and with some new stores recently EBIT.
The.
And some trials and collaborating on it so could you maybe take us to your what the timelines on on the trials and when do you expect to be about a day and sort of action for that thanks.
Sure so from a liberal and gross margin for respect I'll start with with pricing for the broiler, which is very important in terms of the overall profitability of the product now that we've launched in the <unk>, we have price the product.
Premium to the current therapies on the market really consistent with some of the other products that abroad significant envision and some of our other categories such as dermatology you'd see will grow a price to the premium similar to that so we would expect us liberal will be a high margin product for us consistent with the overall companion portfolio, which typically us.
Above overall gross margin level, so that'll be a positive contributor to gross margin overtime in terms of ASF and our development for vaccines as we said before this is a very complicated a disease state and it's going to take many years to find the solution. We are active and those development studies, but it will be a multiyear.
Timeframe before we find a solution for Africans and fever.
I think our next question Kathy minor was Cowan and company. Please go ahead.
Okay. Thank you for your question. Please first on what Grella can you clarify and believing a problem and he said that you expected approval of book Grella later in the day and to learn to you and you can.
Answering questions filing timing or some other dynamic here and.
The second question, a little bigger picture on business development and just.
And pretty quiet on terms of him and and the here can you comment a little bit about your outlook for the rest of 2021 and some of the areas and eat.
And on there. Thank you.
Thanks, Kathy and yes, as we mentioned we are expecting the approval on both of us roller and for lengthy and.
And 2022.
There's nothing specific about weiland relative actually later.
Confident and optimistic any approve.
Approval on both of those and as we get closer will be able to price more specific guidance on revenue and lodge timing et cetera, but there's nothing specific as to why a umbrella and I'm going to.
Maybe later and the year that for like the interest of handling of conditions and and back and forth with the regular sales Glenn too I think the second yeah, so from and M&A perspective, and our areas of focus for 2021, So business development and remains a key area.
And part of our capital allocation strategy and we may focused on that couple of areas. We continue to to pursue consistent with what we've discussed in the past us any specific geography, where we may have an opportunity to gain additional share and or presence and an area that we may not be at the level of market share that we are globally. Those are areas that we will continue to focus.
On and look to bring and additional products into our portfolio on so many of the areas that weaves stress those areas of strategic importance to us with us.
And that's in areas such as for Susan livestock farming genetics diagnostics those areas that we will also continue to remain focused on as well as if they're early development assets as well that we believe with the strength of R&D portfolio, and we can generate greater value than the existing company. So we remain focused on M&A reevaluate many opportunities and and we will look too.
To continue to use that as as primary for a couple of allocation moving forward.
Okay. Our next question from David Risinger with Morgan Sparingly. Please go ahead.
[laughter].
Yes, thanks very much.
Hi, Chris and and see.
From Alaska the exceptional performance.
I think you hear my six year old puppy on the background market and I'm wondering if you have a a.
And barking from.
Yeah.
And and anyway.
So.
And you just move here, a little bit hopefully my call and long cut out so could.
And could you provide additional details on companion and animal innovation prospects beyond man.
Monoclonal antibodies for pain, it would be helpful to understand areas of unmet need and the potential cadence of material new companion animal product introductions and coming years and I know that you can only comment on.
And that's at a high level, but but anything you can offer would be helpful.
And then second give.
Given likely inflationary pressures.
Add on costs.
What is your plan for product price increases and companion and animal and livestock. Thank you.
Thanks, David and thank you ever on a call where we actually welcome your dogs Barking and it that's fine.
And no worries on that.
We are quite excited with regards to our innovative portfolio and both I companion animal and livestock and as you think about contained and animal we're really focused on continuing to grow our franchise and parents set aside and look for additional products, they're continuing to look at exciting areas such as additional add ons and our.
<unk> portfolio and really and we thank the platform of our monoclonal antibodies goes way beyond pain to be honest with you and has lots of other chronic and other conditions. We think that technology will help us and super excited about our portfolio and diagnostic really building new indications.
With our and it gets platform or AI cloud based on diagnostics expanding reference last though I think there's been a really bright future as we look at continuing to expand our pet hair portfolio globally and sign on or if you wanted to take the question with regard to inflation regards to inflation and the impact and we'll have and pricing across our portfolio and.
And so we do expect over the long term to continue to be able to take price increases ranging from from 2% to 3% per year. This year will be a little muted and 2021 because of the impact of the drugs smell low but beyond this year, we do expect to be able to return to that 2% to 3% average pricing.
That will vary based on the product as well as the geography typically on more innovative products were able to take a little bit about that 2% to 3% products that have been on the market a little longer generally go to a little below that 2% to 3% and then and higher inflationary markets. We typically take pricing beyond that 2% to 3%. So we don't see any significant changes to that and.
Short to medium term and and and the fact on a 2021 because of the impact of the drugs and all that we will be below that two to three per cent.
Thank you. Our next question is from Nathan and Rich with Goldman Sachs. Please go ahead.
Hi, good morning, Thanks for the questions maybe.
And is it going back to the launch of Liberal influenza and Europe, I guess Clinton was.
Given your experience with.
The kind of early feedback from that and has that changed your expectations around what the launch curves could look like us. These are kind of new products to treat pain.
So just wanted to get your kind of updated thoughts on what you think kind of uptake will look like and should we think about the and launched or maybe similar to the darn portfolio kind of give and the both both of these therapies are relatively kind of innovative.
Their lunch.
Thank you I think we are very bullish with regards to the lines carpet and bulk labella and fell NCI and the issue I think we're now just and early experiences for lengthy I and I think that's probably a little earlier, there and again I think we fed on I think a little bit previously I do think the lodge credit are going to look different between liberal and fell on pay a little day.
Liberal is going to enter and established market and the great news and the rest are already very comfortable with and tactical amount of Paul Antibiosis and insider point. So I think you'll see a really nice uptick and I think we'll do very well there. So let day is a little different and you have to get more cats to the clinic, you happy and Medicalize, those cats and treat them, it's a little harder to Ohn's OA and.
Cats.
And that being said, we will have a much better sense as we get to the next quarter and since we're just beginning early experience right now we're really bullish on net and the medium term how fast the uptake happened I think for the experienced which is what we're and right now and we'll be able to better and format. If we get for the next quarter, but.
The science behind the safety efficacy is really really strong and what's different us we've talked about for collecting us. They really are very few alternatives for cats. So if we can build a market, which I think they'll let us as demonstrated the ability to do.
We're really excited for what that launch curve will be will be better informed us. He finished early experienced Richard just and now and and you add on that one and I was just echo and you said at Christmas and they're very excited by the feedback that we saw with the earlier experience program. It does give us even greater confidence and more enthusiasm around the potential for these products and the to you and globally and we're continuing to update on for.
Okay based on the feedback that we get.
And our next question is from Chris shot with J P. Morgan and please go ahead.
Great. Thanks, so much for the questions on.
A couple of US here just on trio. Thanks for competition on expected until the second half of 22 does that change for you are thinking about kind of peak market share potential for the product, giving you have this kind of three year window to really establish herself and the market prior to to seeing any type of real competition here and then second and how you talk to touch on this a little bit before but first of all and lives.
Stuck in general it seems a growth for very strong started the year and they were part of that is direction, but with reopening seeming to go pretty well and most markets. So far are you feeling better about these markets.
And and the year or you're still on the cautious just given kind of some of the and it's uneven openings that we're seeing across the world. Thanks. So much.
And thanks for all Terry Glenn Delta and that we are very optimistic, Ontario and.
Ultimately.
Changes occur and a little bit of how fast and we get that on vacation on the market, but I think it's important as I mentioned in my earlier these products still grow even though and competition enters and.
And I think this is something we keep underscoring you to work and compared to US there to market. It is growing like crazy and taking share I think when you put the marketing muscle and the technical experienced muscle us, let us behind the product and and even with competition and we fell effect. These products to grab us. So we will probably build our share faster, but and we do expect even with competition and.
And that these products and and these category will continue to grow also Brittany and more people into prescription product vs. Some of the over the counter really bringing new solutions I think we'll continue to grow these products and a longer term.
And I felt anything that and attracted livestock Juan.
And just to say obviously.
The long run on the market alone and better in terms of accelerating that that peak sales curve, but for Christmas point. This is a very large market and we do see products on the market and franchises on the market that are approaching $1 billion today, even without a triple therapy and the us. So we think there's significant opportunity for future growth.
For this franchise in terms of livestock, we are off to a strong start and we do things at the reopening trends are positive for the overall and we will health industry and the growth and livestock and we're also very pleased with the performance that we've seen and many of our key markets and particularly outside of the us markets, such as China, and Brazil, and what we've been able to accomplish.
And we expect those trends to continue to be very positive. Obviously, we do have some dynamics, particularly to our portfolio within my stock with the impact of drags and but overall the fundamentals and the industry are many positive profitability us up from any of our producers, which is also very encouraging for the overall industry and we think will be positive for the longer term outlook for large book.
And next question is from Greg Gilbert with Truest Securities. Please go ahead.
Good morning closest great free and John for Greg Gilbert on.
On international livestock.
And and robust growth and a quarter and and you spoke to the dynamics and China and some other market has a strong demand trends for the overall business continued and the and the second quarter and how are you thinking about growth for international livestock for the full year. Thank you.
So just when you look at our overall livestock portfolio globally. We grew about 8%. This quarter. As you mentioned that was really driven by the international growth on 17% and as we said enough February call. We do expect that globally, the livestock business will grow and and the low single digits that hasn't changed materially.
Just on the strong performance that we saw and the and the first quarter. So.
That growth, we would expect international livestock to grow more rapidly than the us really driven by the dynamics with China and Brazil.
But still expecting single, mostly on digit growth for our livestock business for the year.
From next to new lawn and tie with city. Please go ahead.
Hi, Good morning, actually my question and I think.
And could you comment on and I need to take ownership and yeah.
Average alright, and you could companion name and what if anything's going forward and you'll get your room and I remember and he expected to motivate Juan.
And I will return to the pieces and you have a day to talk from that Trump. Thank you.
Sure and do you think about pet care and.
We've been.
Try and it's driving it is the increased pet ownership, which has been changing and there was a little bit of a fear US. We were in Q3 of last year with a lot of these dogs be returned our cats and return to Rehomed and we really haven't seen significant trend aircell and we thank thee.
Increased pet ownership and.
And if people go back to work.
Most people are going on flexible arrangement, they are still going to be home with her had more than probably they weren't before and they built a bond with those paths and make note of things and they built habits that we think will be sustained if we do that and again and the other important and try and carry a truly for owning these pets and millennials engender, who tend to spend more per pack and.
So we really continue to see pet ownership trends and.
<unk> per pack.
Continuing I mean is it going to be 10% every quarter I'm not sure but.
Historically, just to remind you I think it was 5% to 6% historically, so it's still a very strong growth driver overall for the industry and I think these traders may be higher than what it historically has been on and go forward basis.
Just give interest adapting the past and increased focus on the patents and important part of the family.
Thank you we will go next to David Steinberg Jeffries. Please go ahead.
Yeah. Thanks, I just have one question to follow up on potential trio competition and.
Year ago, you expecting competition and the second half of this year and then you pushed it and.
Next year and now second half of next year and so just curious I know you said you have limited visibility but.
What do you think of sources of the delay and might be would it be technical manufacturing and formulation issues or heightened regulatory issues, you know delays and inspection or FDA looking for different things.
And just curious since you since you initially thought it would be relatively soon what could be the technical and regulatory issues surrounding the potential delay and the lots of the competitive thanks.
Thanks, David and I have to take care of it very good list, there and potential reason honest answer and we don't really know.
Wider specific the ways and.
Similar delays for different companies.
It's very difficult for us to.
And there's not a lot and create detailed information. So I mean hardware sales and why does that we consider where all the ones you get nice and to be perfectly honest.
Which one it is for which company and I'm not really sure and May.
Maybe because they like their first later as example, and one of the companies that for the others. It's not exactly fair got exactly what is driving those delays, though and I.
And I wish I could be a little more helpful. Here, but I don't think we don't really know.
And but it appears we have no further questions and I'll return to Florida for speakers for any closing remarks.
Okay, well thanks for your questions today and for your continued interest and that way and.
Look forward to keeping you updated us our business throughout the year and continuing to deliver our results and innovation. Thank you and our customers expect though thanks, so much for this day while everybody.
And this will conclude today's program. Thanks for your participation you may now disconnect have a great day.
[music].